MIMOSA Diagnostics is a mobile health platform that analyzes tissue oxygenation and blood flow to enable early assessment of foot ulcers. The company focuses on the prevention and monitoring of diabetic foot ulcers (DFUs) and the amputations they can cause.
Why we invested ?
The diabetic foot care epidemic is significant, costing the U.S. system ~$60 billion annually. In fact, 25% of people with diabetes develop ulcers in their lifetime, resulting in 1.7 million ulcers per year and 120,000 lower extremity amputations per year in the United States. Nevertheless, most existing solutions are in the post-ulcer space rather than the pre-ulcer space.
MIMOSA’s diagnostic technology could save health systems substantial costs and provide peace of mind to diabetic patients.